RBC Capital Initiates Coverage On Solid Biosciences with Outperform Rating, Announces Price Target of $18

RBC Capital analyst Luca Issi has initiated coverage on Solid Biosciences (NASDAQ: SLDB) with an Outperform rating. The firm has set a price target of $18 for the stock.